Impax Asset Management Group plc Has $150.27 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Impax Asset Management Group plc lowered its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 0.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,051,939 shares of the biotechnology company's stock after selling 6,230 shares during the quarter. Impax Asset Management Group plc owned 1.88% of Repligen worth $150,267,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Blue Trust Inc. grew its holdings in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 127 shares during the last quarter. Resources Management Corp CT ADV acquired a new stake in Repligen in the 3rd quarter valued at about $37,000. Quarry LP increased its holdings in Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 239 shares in the last quarter. UMB Bank n.a. increased its holdings in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 110 shares in the last quarter. Finally, Global Retirement Partners LLC raised its position in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 129 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Price Performance

RGEN traded down $6.27 on Thursday, reaching $156.54. The company had a trading volume of 438,659 shares, compared to its average volume of 616,262. The company has a fifty day moving average of $155.68 and a 200-day moving average of $148.65. The company has a market capitalization of $8.77 billion, a P/E ratio of -306.94, a PEG ratio of 4.54 and a beta of 0.99. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a one year low of $113.50 and a one year high of $203.13.

Remove Ads

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million during the quarter, compared to analysts' expectations of $167.58 million. As a group, equities research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently commented on RGEN shares. Royal Bank of Canada lifted their price objective on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday, February 21st. HC Wainwright reissued a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. TD Cowen initiated coverage on Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 price target for the company. Finally, Canaccord Genuity Group lifted their price objective on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $181.00.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.